Frazier Life Sciences Management, L.P. Portfolio Holdings

Frazier Life Sciences Management, L.P.

  • $1.9 Billion
  • Q1 2024

Frazier Life Sciences Management, L.P. has filed its 13F form on May 15, 2024 for Q1 2024 where it was disclosed a total value porftolio of $1.9 Billion distributed in 50 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Krystal Biotech, Inc. with a value of $176M, Mirum Pharmaceuticals, Inc. with a value of $163M, Hille Vax, Inc. with a value of $163M, Alpine Immune Sciences, Inc. with a value of $124M, and Phathom Pharmaceuticals, Inc. with a value of $107M.

Examining the 13F form we can see an increase of $279M in the current position value, from $1.63B to 1.9B.

Frazier Life Sciences Management, L.P. is based out at Menlo Park, CA

Below you can find more details about Frazier Life Sciences Management, L.P. portfolio as well as his latest detailed transactions.

Portfolio value $1.9 Billion
Healthcare: $1.9 Billion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$4.11B
$176 Million 9.23% of portfolio
988,460
Q3 2023 Reduced 0.18%
$883M
$163 Million 8.57% of portfolio
6,495,392
Q4 2023 Added 0.39%
$406M
$163 Million 8.54% of portfolio
9,781,472
Q1 2023 Added 0.24%
$0
$124 Million 6.52% of portfolio
3,131,008
Q4 2023 Added 4.86%
$369M
$107 Million 5.64% of portfolio
10,109,279
Q2 2023 Added 20.25%
$4.15B
$106 Million 5.54% of portfolio
3,415,604
Q1 2024 Added 25.3%
$1.99B
$94.9 Million 4.98% of portfolio
2,190,179
Q1 2024 Reduced 7.64%
$503M
$87.1 Million 4.57% of portfolio
8,785,284
Q1 2024 Added 0.24%
$4.17B
$77.8 Million 4.09% of portfolio
1,139,405
Q1 2024 Reduced 2.15%
$879M
$65 Million 3.41% of portfolio
1,787,527
Q2 2022 Added 26.13%
$1.08B
$60.3 Million 3.16% of portfolio
3,303,567
Q1 2024 Added 23.86%
$356M
$57 Million 2.99% of portfolio
4,142,855
Q1 2024 Added 93.33%
$4.31B
$52 Million 2.73% of portfolio
885,165
Q4 2023 Added 44.15%
$736M
$48.5 Million 2.55% of portfolio
3,014,349
Q3 2023 Added 2.38%
$287M
$43.7 Million 2.3% of portfolio
3,687,867
Q1 2024 Added 1.81%
$1.61B
$42.1 Million 2.21% of portfolio
1,561,230
Q1 2024 Added 2.51%
$427M
$35.6 Million 1.87% of portfolio
1,204,867
Q3 2023 Added 21.11%
$2.44B
$33.6 Million 1.76% of portfolio
746,479
Q3 2022 Added 10.76%
$3.36B
$32.1 Million 1.69% of portfolio
997,455
Q3 2023 Added 16.73%
$381M
$29.5 Million 1.55% of portfolio
4,623,324
Q1 2024 Added 23.39%
$150M
$25.5 Million 1.34% of portfolio
7,381,090
Q4 2023 Added 7.27%
$753M
$24.8 Million 1.3% of portfolio
1,148,591
Q1 2024 Added 30.35%
$1.71B
$22.9 Million 1.2% of portfolio
1,455,837
Q1 2024 Added 42.48%
$386M
$22.1 Million 1.16% of portfolio
1,502,788
Q1 2024 New
$466M
$19.9 Million 1.05% of portfolio
4,000,000
Q3 2023 New
$6.35B
$16.6 Million 0.87% of portfolio
393,000
Q3 2022 Added 94.3%
$1.99B
$15.3 Million 0.8% of portfolio
523,166
Q4 2023 Added 79.17%
$787M
$15.1 Million 0.79% of portfolio
1,069,244
Q1 2024 New
$175M
$14.9 Million 0.78% of portfolio
2,816,294
Q1 2024 New
$681M
$13.6 Million 0.72% of portfolio
832,220
Q1 2024 Reduced 18.92%
$206M
$13.3 Million 0.7% of portfolio
1,952,857
Q1 2024 New
$360M
$12.8 Million 0.67% of portfolio
2,867,750
Q1 2024 New
$1.76B
$11.8 Million 0.62% of portfolio
285,331
Q2 2022 Added 5.55%
$367M
$11.6 Million 0.61% of portfolio
1,000,000
Q1 2024 Reduced 50.0%
$2.44B
$8.7 Million 0.46% of portfolio
470,338
Q1 2024 Reduced 35.65%
$527M
$6.29 Million 0.33% of portfolio
936,576
Q1 2024 Reduced 53.06%
$1.63B
$5.6 Million 0.29% of portfolio
203,684
Q1 2022 New
$38.6M
$4.51 Million 0.24% of portfolio
1,388,889
Q3 2023 New
$56.2M
$2.65 Million 0.14% of portfolio
1,030,878
Q4 2023 Reduced 27.95%
$69.4M
$2.19 Million 0.11% of portfolio
1,709,907
Q2 2023 Added 18.68%
$68.7M
$327,000 0.02% of portfolio
264,377
Q1 2023 Reduced 8.89%
Anaptysbio Inc
-
$0 0.0% of portfolio
-
Q1 2022 New
Structure Therapeutics Inc
-
$0 0.0% of portfolio
-
Q1 2024 Added 98.37%
-
$0 0.0% of portfolio
-
Q1 2024 Added 0.79%
Cg Oncology Inc
-
$0 0.0% of portfolio
-
Q1 2024 New
Disc Medicine Inc
-
$0 0.0% of portfolio
-
Q4 2023 Added 19.85%
Metagenomi Inc
-
$0 0.0% of portfolio
-
Q1 2024 New
-
$0 0.0% of portfolio
-
Q4 2022 New
Soleno Therapeutics Inc
-
$0 0.0% of portfolio
-
Q1 2024 Added 88.34%

Summary

  • Portfolio
  • No. of Stocks 50
  • Current Value $1.9 Billion
  • Prior Value $1.63 Billion
  • Filing
  • Period Q1 2024
  • Filing Date May 15, 2024
  • Form Type 13F-HR
  • Activity in Q1 2024
  • New Purchases 7 stocks
  • Additional Purchases 13 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 6 stocks
Track This Portfolio

Track Frazier Life Sciences Management, L.P. Portfolio

Follow Frazier Life Sciences Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email